

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 57106

Title: Prolonged time interval to surgery following neoadjuvant concurrent chemoradiotherapy may improve disease-free survival and pathologic response in rectal cancer

Reviewer's code: 00729304

Position: Peer Reviewer

Academic degree: MD

Professional title: Associate Professor

Reviewer's Country/Territory: Iran

Author's Country/Territory: China

Manuscript submission date: 2020-05-26

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-05-28 06:39

Reviewer performed review: 2020-05-28 08:10

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Dear Authors, Thank you for your nice submission. Comments: 1. There is no information regarding radiation therapy technique (2D, 3D, IMRT?) in the method section. As well, there is no information and analysis regarding the total mean dose of radiation between groups. 2. Currently, oxaliplatin-containing chemoradiotherapy is generally not considered a standard approach for long-course chemoradiotherapy in rectal cancer, due to more treatment-related toxicity and no better outcomes compared with standard fluoropyrimidine-based chemoradiotherapy. What is your rationale for the selection of an oxaliplatin-containing regimen in your treatments? 3. There is no data about the cycles of induction chemotherapy before surgery? induction chemotherapy before and after CRT and before surgery can induce more tumor shrinkage and provide a higher response rate in group B. 4. In table 2, there is a mistake and you missed patients with ypT0! Regards,